Document Detail


Primary treatment of macroprolactinomas with Parlodel LAR.
MedLine Citation:
PMID:  3414319     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Five patients, 3 women and 2 men, with macroprolactinomas characterized by extrasellar extension and basal plasma prolactin levels ranging from 4.6 to 102 U/l received six monthly injections of 50-100 mg Parlodel LAR, an injectable long-acting repeatable form of bromocriptine. The following observations were made: 1. Plasma prolactin levels fell dramatically in all patients and values in the normal range were obtained in 3 patients. 2. In all patients, the onset of tumour reduction was visible on CT scans made one week after the first Parlodel LAR injection. After six Parlodel LAR injections, tumour size was reduced by more than 75% in 3 patients and by 50-75% in two patients. 3. Diminished visual acuity (one patient), bitemporal hemianopia (2 patients), and oculomotor and trochlear nerve dysfunction (one patient) were restored to normal after the first Parlodel LAR injection. 4. Hypogonadism normalized in 2 patients and improved in one patient, whereas plasma gonadotropins remained low in the 2 postmenopausal women. In one patient with hypothyroidism and hypocorticism, thyroid and adrenal functions normalized. It is concluded that bromocriptine retard (50-100 mg monthly) is a useful alternative for oral treatment of patients with prolactinomas, especially in those patients with compliance problems on oral bromocriptine therapy.
Authors:
J W van 't Verlaat; I Lancranjan; M J Hendriks; R J Croughs
Related Documents :
6739539 - The metyrapone test in manic patients and healthy subjects.
8306479 - Adrenocorticotrophin stimulation and hla polymorphisms suggest a high frequency of hete...
20446239 - Adrenomedullary function in patients with nonclassic congenital adrenal hyperplasia.
20606359 - Subclinical hypercortisolism among polycythemia vera patients.
19509479 - Growth hormone deficiency and antipituitary antibodies in a patient with common variabl...
6814279 - Hypothalamic-pituitary function in patients with congenital malformations accompanied b...
19377229 - Spirometry parameters in patients undergoing hemodialysis with bicarbonate and acetate ...
21277129 - Thermolabile cpt ii variants and low blood atp levels are closely related to severity o...
2862819 - Aminophylline increases the toxicity but not the efficacy of an inhaled beta-adrenergic...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Acta endocrinologica     Volume:  119     ISSN:  0001-5598     ISO Abbreviation:  Acta Endocrinol.     Publication Date:  1988 Sep 
Date Detail:
Created Date:  1988-10-13     Completed Date:  1988-10-13     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  0370312     Medline TA:  Acta Endocrinol (Copenh)     Country:  DENMARK    
Other Details:
Languages:  eng     Pagination:  51-5     Citation Subset:  IM    
Affiliation:
Department of Neurosurgery, University Hospital Utrecht, The Netherlands.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adenoma / drug therapy*,  radiography,  secretion
Adolescent
Adult
Aged
Bromocriptine / administration & dosage*,  adverse effects
Delayed-Action Preparations
Female
Humans
Male
Middle Aged
Pituitary Neoplasms / drug therapy*,  radiography,  secretion
Prolactin / secretion*
Tomography, X-Ray Computed
Visual Acuity / drug effects
Chemical
Reg. No./Substance:
0/Delayed-Action Preparations; 25614-03-3/Bromocriptine; 9002-62-4/Prolactin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  A method for selective infusion in the thyroid artery of the rat and mouse.
Next Document:  Detection of corticosteroid binding globulin in parotid fluids: evidence for the presence of both pr...